key: cord-0835248-t8eht2jg
authors: Chistolini, Antonio; Ruberto, Franco; Alessandri, Francesco; Santoro, Cristina; Barone, Francesco; Puzzolo, Maria Cristina; Ceccarelli, Giancarlo; De Luca, Maria Lucia; Mancone, Massimo; Alvaro, Domenico; Pulcinelli, Fabio M.; Martelli, Maurizio; Foà, Robin; Pugliese, Francesco
title: Effect of low or high doses of low molecular weight heparin on thrombin generation and other hemostasis parameters in COVID‐19 critical patients
date: 2020-07-06
journal: Br J Haematol
DOI: 10.1111/bjh.17003
sha: 7b667a125d84817998b671bee413236cf137f8f5
doc_id: 835248
cord_uid: t8eht2jg

The clinical picture of the coronavirus 2 (SARS‐CoV‐2)/COVID‐19‐related acute respiratory syndrome is often associated with a coagulopathy. An elevated D‐dimer has been linked with an unfavorable prognosis in COVID‐19 patients.

The clinical picture of the coronavirus 2 (SARS-CoV-2)/COVID-19-related acute respiratory syndrome is often associated with a coagulopathy. 1 An elevated D-dimer has been linked with an unfavorable prognosis in COVID-19 patients. In a recent cohort study, 71% of patients who died matched the International Society of Thrombosis and Hemostasis (ISTH) criteria for disseminated intravascular coagulation (DIC) 2 , while this percentage was only 0.6% in patients who survived. 3 In two recent studies, the authors described the presence of a hypercoagulability state in COVID-19 affected patients, in the absence however of pathognomonic signs of DIC. 4, 5 Thus, the nature of this coagulopathy is not fully understood. Clinical evidences suggest that this COVID-19-related

This article is protected by copyright. All rights reserved coagulopathy is associated with an increased risk of both venous and arterial thrombotic events. 6, 7 The management of these thromboembolic complications is based on the use of heparin in the absence of contraindications (active bleeding and a platelet count <30x10 9 /l). 8 However, the efficacy of heparin remains to be validated. The benefit/risk of using heparin, as well as the timing of starting anticoagulants and at which dose, is controversial. 9,10 We carried out an observational study to investigate different coagulation parameters, in particular thrombin generation assay (TGA), in COVID-19 critical patients and to correlate these results with different doses of low molecular weight heparin (LMWH) administered to these subjects. 

This article is protected by copyright. All rights reserved endothelial derangement. These altered coagulation parameters observed in COVID-19 patients could be related to an active response due to a marked alveolar inflammatory cell infiltrate with a consequent systemic cytokine storm. On the contrary, we found laboratory parameters compatible with a diagnosis of DIC only in few patients: a prolonged PT was observed in 29.6% of cases, a prolonged aPTT in 14.8%, a reduced fibrinogen in 29.6%, a reduced AT in 37% and a decreased platelet count in 7.4% (Table 1 ). We cannot exclude that these results may be associated with the heparin administration which was ongoing in all patients from at least 2 days prior to the blood collection. With regard to TGA, we observed an overall increased mean values of the T-Lag 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis

Online ahead of print

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on Thrombosis and Hemostasis

Work partly supported by Associazione Italiana Ricerca sul Cancro (AIRC), Special 5x1000Program Metastases (21198), Milan (Italy) to RF. 

This article is protected by copyright. All rights reserved